by admin_63069 | Jul 26, 2021 | Related Topics
The acceptance of the concept of focal therapy for prostate cancer has been growing over the past 20 years and it is becoming part of the standard range of treatments to be considered by patients and clinicians.
by admin_63069 | Jul 23, 2021 | Related Topics
Findings from the VISION trial support adoption of 177Lu-PSMA-617 as a standard of care in patients with mCRPC, according to investigators.
by admin_63069 | Jul 19, 2021 | Related Topics
What remains unclear is whether the risk for both prostate cancer development and the risk of progression to lethal diseasecan be offset by adherence to a healthy lifestyle.
by admin_63069 | Jul 15, 2021 | Related Topics
Michael Morris, MD joins Charles Ryan, MD in a discussion on the United States (US) FDA Approval of PYLARIFY®, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging agent.
by admin_63069 | Jul 11, 2021 | Related Topics
Where we currently stand and where research is heading
by admin_63069 | Jul 7, 2021 | Related Topics
Leonard S. Marks, MD, moderated “Transrectal mpMRI Fusion Biopsy” during the Southwest Prostate Cancer Symposium 2020 virtual conference in December 2020.
